Y-mAbs Therapeutics's 15min chart sees MACD Death Cross, KDJ Death Cross trigger.

Based on the 15-minute chart for Y-mAbs Therapeutics, a MACD Death Cross and KDJ Death Cross occurred on August 12, 2025, at 13:00. This suggests that the stock price has the potential to continue declining, with momentum shifting towards the downside and potentially further decreasing.

Y-mAbs Therapeutics (NASDAQ: YMAB) faced a significant setback as its stock was downgraded from a "Buy" to a "Hold" rating by Truist Securities on August 12, 2025. The downgrade comes amidst a series of developments, including an acquisition offer from SERB Pharmaceuticals and recent technical indicators suggesting a potential downward trend.

The acquisition offer by SERB Pharmaceuticals, valued at approximately $412 million, represents a 105% premium to Y-mAbs' closing share price on August 4, 2025. The deal is expected to close by the fourth quarter of 2025, contingent on customary conditions and regulatory approvals. Despite the acquisition, the company reported a 14.4% decline in revenue to $19.52 million in the second quarter of 2025, driven by lower sales of Danyelza, its FDA-approved therapy for high-risk neuroblastoma [2].

Technical indicators have also pointed to a potential downward trend for Y-mAbs Therapeutics. On August 12, 2025, at 13:00, a MACD Death Cross and KDJ Death Cross occurred, suggesting a potential shift in momentum towards the downside. This technical signal, based on the 15-minute chart, indicates that the stock price may continue to decline [3].

Analysts have responded to these developments with mixed signals. While Truist Securities has downgraded the stock, Clear Street has reiterated a "Buy" rating and raised its price target to $17. Meanwhile, H.C. Wainwright has adjusted its price target to $11, maintaining a "Buy" rating [1].

Investors should closely monitor these developments and consider the implications of the pending acquisition and the technical indicators for Y-mAbs Therapeutics' future performance. The company's strategic focus has shifted towards executing the merger process, which may impact its operational efficiency and financial performance in the near term.

References:
[1] https://www.investing.com/news/analyst-ratings/ymabs-therapeutics-stock-downgraded-to-hold-by-truist-after-serb-acquisition-93CH-4171219
[2] https://www.ainvest.com/news/mabs-therapeutics-2025-q2-earnings-narrowed-losses-pending-acquisition-2508/
[3] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3U02UT:0-y-mabs-therapeutics-inc-expected-to-post-a-loss-of-25-cents-a-share-earnings-preview/